Related references
Note: Only part of the references are listed.O6-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib
A. J. Watson et al.
BRITISH JOURNAL OF CANCER (2009)
The potential role and application of PARP inhibitors in cancer treatment
Anthony J. Chalmers
BRITISH MEDICAL BULLETIN (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Phase I Study of the Poly (ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
Ruth Plummer et al.
CLINICAL CANCER RESEARCH (2008)
4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
Keith A. Menear et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Temozolomide for the treatment of metastatic melanoma: A systematic review
Ian Quirt et al.
ONCOLOGIST (2007)
DNA glycosylase recognition and catalysis
JC Fromme et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2004)
Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials
TK Eigentler et al.
LANCET ONCOLOGY (2003)
The therapeutic potential of poly(ADP-ribose) polymerase inhibitors
L Virág et al.
PHARMACOLOGICAL REVIEWS (2002)
Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components
L Tentori et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2001)
Development and application of a sensitive and rapid immunoassay for the quantitation of N7-methyldeoxyguanosine in DNA samples
KL Harrison et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2001)
Share Paper
